GlassScriptPhysician profile
Rajesh A Shetty
NPI 1255374641
$12,493.81
in general payments reported to CMS, 2019-2025
27 companies · $5,730 in 2025
The $5,730 reported for 2025 was more than what 89% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $259 · 2020: $129 · 2021: $115 · 2022: $430 · 2023: $762 · 2024: $5,069 · 2025: $5,730.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $7,193 · Food and Beverage: $3,471 · Travel and Lodging: $883 · Gift: $14.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $7,193.01 |
| Food and Beverage | $3,470.92 |
| Travel and Lodging | $882.50 |
| Gift | $14.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $8,398.92 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $982.38 | 2021-2025 | Fasenra, Tezspire, Symbicort |
| Boehringer Ingelheim Pharmaceuticals, INC. | $610.99 | 2022-2025 | Ofev, Jascayd |
| Olympus Corporation of The Americas | $485.12 | 2022-2023 | Single Use Suction Valve (Sterile) |
| Glaxosmithkline, LLC. | $376.14 | 2019-2025 | Nucala, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $310.47 | 2024-2025 | Dupixent |
| Genzyme Corporation | $294.68 | 2024-2025 | |
| Sunovion Pharmaceuticals INC. | $183.62 | 2019-2020 | |
| Mylan Specialty L.P. | $132.26 | 2024 | Yupelri |
| Inspire Medical Systems, INC. | $91.91 | 2024 | Inspire |
| Insmed, INC. | $75.70 | 2023-2024 | Arikayce |
| Grifols USA, LLC | $68.91 | 2022-2025 | Prolastin-C Liquid |
| Philips North America LLC | $62.60 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $61.97 | 2019-2025 | Uptravi, Opsumit |
| Verona Pharma, INC. | $47.48 | 2025 | Ohtuvayre |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $45.10 | 2025 | Zepbound, Mounjaro |
| Cook Medical LLC | $41.27 | 2020-2024 | Zilver Vena |
| Janssen Pharmaceuticals, INC | $37.06 | 2021 | |
| Abbvie INC. | $30.21 | 2021-2023 | Avycaz |
| Ani Pharmaceuticals, INC. | $29.84 | 2024-2025 | Purified Cortrophin Gel |
| Csl Behring | $27.30 | 2020 | |
| Mallinckrodt Hospital Products INC. | $24.86 | 2025 | Acthar |
| Baxter Healthcare | $20.59 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Circassia INC. | $17.15 | 2019 | |
| Electromed, INC. | $15.98 | 2025 | Smartvest |
| Itamar Medical INC | $13.80 | 2022 | |
| United Therapeutics Corporation | $7.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajesh Shetty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.